NeuroBo Q2 net loss $10.1M; cash $27.9M; DA-1726 SAD fully enrolled

MetaVia Inc.

2024-Q2 EPS reported -$3.19

Net loss Q2 2024 $10.1M ($1.85/sh) vs $0.7M ($0.15/sh) Q2 2023; R&D expense rose to $8.1M from $2.4M.
Cash $27.9M at June 30, 2024; expects to fund operations into Q2 2025; closed $20M upfront financing with up to $50M milestone warrants.
DA-1726 SAD Part 1 fully enrolled (45 patients); top-line data expected Q3 2024; MAD Part 2 top-line Q1 2025.
DA-1241 MASH Phase 2a top-line results expected Q4 2024; pre-clinical combination data with semaglutide presented.
Signed joint research agreement for once-monthly DA-1726 formulation; out-licensed NB-01 for painful diabetic neuropathy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.